Promising combo targets Hard-to-Treat lymphoma
NCT ID NCT07555470
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This study tests a combination of two drugs, mosunetuzumab and zeprumetostat, in about 80 people with follicular lymphoma, a type of blood cancer. Participants include those with newly diagnosed high-risk or low-tumor-burden disease, as well as those whose cancer has returned or not responded to prior treatment. The goal is to see if the combination improves complete response rates and delays disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, China
Contact
Conditions
Explore the condition pages connected to this study.